Adverse Drug Reactions Relevant to Drug Resistance and Ineffectiveness Associated with Meropenem, Linezolid, and Colistin: An Analysis Based on Spontaneous Reports from the European Pharmacovigilance Database

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2023 May 27

PMID 37237821

Authors

Bogdan Ioan Vintila

Anca Maria Arseniu

Anca Butuca

Mihai Sava

Victoria Birlutiu

Luca Liviu Rus

Dan Damian Axente

Claudiu Morgovan

Felicia Gabriela Gligor

Affiliations

Soon will be listed here.

Abstract

Antimicrobial resistance is considered one of the major threats to public health and is an important factor that influences the patient's outcome in the intensive care unit. Pharmacovigilance can help raise awareness of potential drug resistance (DR) or ineffectiveness (DI) through adverse drug reaction reports that are submitted to different spontaneous reporting systems. Based on spontaneous Individual Case Safety Reports from EudraVigilance, we conducted a descriptive analysis of adverse drug reactions associated with meropenem, colistin, and linezolid, with a focus on DR and DI. Of the total adverse drug reactions (ADRs) reported for each analyzed antibiotic by 31 December 2022, between 2.38-8.42% and 4.15-10.14% of the reports were related to DR and DI, respectively. A disproportionality analysis was conducted to evaluate the frequency of reporting adverse drug reactions relevant to the DR and DI of the analyzed antibiotics compared to other antimicrobials. Based on the analysis of the collected data, this study underlines the importance of post-marketing drug safety monitoring in raising a warning signal regarding antimicrobial resistance, thereby potentially contributing to the reduction in antibiotic treatment failure in an intensive care setting.

Citing Articles

Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database.

Vonica R, Morgovan C, Butuca A, Pumnea M, Cipaian R, Frum A Cancers (Basel). 2025; 17(4).

PMID: 40002260 PMC: 11853327. DOI: 10.3390/cancers17040663.

Advances in the application of colorectal cancer organoids in precision medicine.

Zhang Y, Meng R, Sha D, Gao H, Wang S, Zhou J Front Oncol. 2024; 14:1506606.

PMID: 39697234 PMC: 11653019. DOI: 10.3389/fonc.2024.1506606.

From Hemorrhagic Shock to Postoperative Complications: Anesthesia, Intensive Care, and Surgical Management of a Young Male With Pulmonary Aspergillosis.

Vargatu-Dinica L, Sava M, Bereanu A, Achim D, Bancila S, Seceleanu C Cureus. 2024; 16(11):e73017.

PMID: 39640161 PMC: 11617599. DOI: 10.7759/cureus.73017.

Evaluating Anesthesia Practices, Patient Characteristics, and Outcomes in Electroconvulsive Therapy: A Two-Year Retrospective Study.

Vintila B, Anghel C, Sava M, Bereanu A, Codru I, Stoica R J Clin Med. 2024; 13(20).

PMID: 39458203 PMC: 11508605. DOI: 10.3390/jcm13206253.

An Assessment of Semaglutide Safety Based on Real World Data: From Popularity to Spontaneous Reporting in EudraVigilance Database.

Butuca A, Dobrea C, Arseniu A, Frum A, Chis A, Rus L Biomedicines. 2024; 12(5).

PMID: 38791086 PMC: 11117978. DOI: 10.3390/biomedicines12051124.

References

Ayoub Moubareck C . Polymyxins and Bacterial Membranes: A Review of Antibacterial Activity and Mechanisms of Resistance. Membranes (Basel). 2020; 10(8). PMC: 7463838. DOI: 10.3390/membranes10080181. View

Gijsen M, Vlasselaers D, Spriet I, Allegaert K . Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine. Antibiotics (Basel). 2021; 10(10). PMC: 8532953. DOI: 10.3390/antibiotics10101182. View

Zazzara M, Palmer K, Vetrano D, Carfi A, Onder G . Adverse drug reactions in older adults: a narrative review of the literature. Eur Geriatr Med. 2021; 12(3):463-473. PMC: 8149349. DOI: 10.1007/s41999-021-00481-9. View

Justo J, Bosso J . Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy. 2014; 35(1):28-33. DOI: 10.1002/phar.1493. View

Vincent J, Rello J, Marshall J, Silva E, Anzueto A, Martin C . International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009; 302(21):2323-9. DOI: 10.1001/jama.2009.1754. View

Cisneros J, Rosso-Fernandez C, Roca-Oporto C, De Pascale G, Jimenez-Jorge S, Fernandez-Hinojosa E . Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. Crit Care. 2019; 23(1):383. PMC: 6883535. DOI: 10.1186/s13054-019-2627-y. View

Moffatt J, Harper M, Boyce J . Mechanisms of Polymyxin Resistance. Adv Exp Med Biol. 2019; 1145:55-71. DOI: 10.1007/978-3-030-16373-0_5. View

Coculescu B . Antimicrobial resistance induced by genetic changes. J Med Life. 2010; 2(2):114-23. PMC: 3018982. View

Elshamy A, Aboshanab K . A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options. Future Sci OA. 2020; 6(3):FSO438. PMC: 7050608. DOI: 10.2144/fsoa-2019-0098. View

10.

Rosso-Fernandez C, Garnacho-Montero J, Antonelli M, Dimopoulos G, Cisneros J . Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study.... Trials. 2015; 16:102. PMC: 4374401. DOI: 10.1186/s13063-015-0614-4. View

11.

Diekema D, Jones R . Oxazolidinones: a review. Drugs. 2000; 59(1):7-16. DOI: 10.2165/00003495-200059010-00002. View

12.

Roberts J, Lipman J . Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009; 37(3):840-51. DOI: 10.1097/CCM.0b013e3181961bff. View

13.

Ferreira J, Placido A, Afreixo V, Ribeiro-Vaz I, Roque F, Herdeiro M . Descriptive Analysis of Adverse Drug Reactions Reports of the Most Consumed Antibiotics in Portugal, Prescribed for Upper Airway Infections. Antibiotics (Basel). 2022; 11(4). PMC: 9028170. DOI: 10.3390/antibiotics11040477. View

14.

Meletis G . Carbapenem resistance: overview of the problem and future perspectives. Ther Adv Infect Dis. 2016; 3(1):15-21. PMC: 4735501. DOI: 10.1177/2049936115621709. View

15.

Postigo R, Brosch S, Slattery J, van Haren A, Dogne J, Kurz X . EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. Drug Saf. 2018; 41(7):665-675. PMC: 5990579. DOI: 10.1007/s40264-018-0647-1. View

16.

Armstrong T, Fenn S, Hardie K . JMM Profile: Carbapenems: a broad-spectrum antibiotic. J Med Microbiol. 2021; 70(12). PMC: 8744278. DOI: 10.1099/jmm.0.001462. View

17.

Gunasekaran S, Mahadevaiah S . Healthcare-associated Infection in Intensive Care Units: Overall Analysis of Patient Criticality by Acute Physiology and Chronic Health Evaluation IV Scoring and Pathogenic Characteristics. Indian J Crit Care Med. 2020; 24(4):252-257. PMC: 7297239. DOI: 10.5005/jp-journals-10071-23384. View

18.

Habarugira J, Harmark L, Figueras A . Pharmacovigilance Data as a Trigger to Identify Antimicrobial Resistance and Inappropriate Use of Antibiotics: A Study Using Reports from The Netherlands Pharmacovigilance Centre. Antibiotics (Basel). 2021; 10(12). PMC: 8698598. DOI: 10.3390/antibiotics10121512. View

19.

Aurilio C, Sansone P, Barbarisi M, Pota V, Giaccari L, Coppolino F . Mechanisms of Action of Carbapenem Resistance. Antibiotics (Basel). 2022; 11(3). PMC: 8944602. DOI: 10.3390/antibiotics11030421. View

20.

Roberts J, Kruger P, Paterson D, Lipman J . Antibiotic resistance--what's dosing got to do with it?. Crit Care Med. 2008; 36(8):2433-40. DOI: 10.1097/CCM.0b013e318180fe62. View